drugset / Trial / NCT02269176

Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

NCT02269176

Phase 3 Completed 330 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Using Losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the treatment of the mild to moderate primary hypertension patients in China

Timeline

Start
2000-07
Primary completion
2001-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Losartan Other / unclassified 50 mg
Comparator Losartan Other / unclassified 100 mg
Subject Telmisartan Other / unclassified 40 mg
Subject Telmisartan Other / unclassified 80 mg